Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Authors: James Lineen, David M.J. Naimark
Journal: Annals of Internal Medicine (2014)

Letters21 January 2014Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney DiseaseJames Lineen, MB BCh, MSc and David M.J. Naimark, MD, MSc, on behalf of the Sunnybrook Nephrology Journal ClubJames Lineen, MB BCh, MScFrom Sunnybrook Health Sciences Centre and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author and David M.J. Naimark, MD, MScFrom Sunnybrook Health Sciences Centre and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author, on behalf of the Sunnybrook Nephrology Journal ClubSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5001-5 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Erickson and colleagues (1) have published an elegant Markov-based cost-effectiveness analysis that extends the results of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial (2) of tolvaptan for the treatment of adult autosomal dominant polycystic kidney disease (ADPKD). The authors indicate that a key input parameter was the change in estimated glomerular filtration rate (eGFR) in patients who would or would not receive chronic tolvaptan therapy. In fact, the parameter that was modeled was the change in the actual GFR. However, because the eGFR is a nonlinear ...References1. Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med. 2013;159:382-9. [PMID: 24042366] LinkGoogle Scholar2. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407-18. [PMID: 23121377] CrossrefMedlineGoogle Scholar3. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12. [PMID: 19414839] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Sunnybrook Health Sciences Centre and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.Disclosures: None disclosed. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L13-1102. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Christopher M. Blanchette , Benjamin Gutierrez , and Keith Friend Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Christopher M. Blanchette , Benjamin Gutierrez , and Keith Friend Metrics 21 January 2014Volume 160, Issue 2Page: 141-142KeywordsAutosomal dominant diseasesCreatinineDrugsEpidemiologyEstimated glomerular filtration ratePolycystic kidney diseaseQuality adjusted life yearsRenal analysisRenal failureSafety ePublished: 21 January 2014 Issue Published: 21 January 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...